• Title/Summary/Keyword: Drug sensitivity

검색결과 467건 처리시간 0.033초

횡문근융해증을 유발하는 음독 약물별 임상경과 분석 (Clinical Analysis of Rhabdomyolysis Complicated with Drug Intoxications)

  • 이미진;김형민;김영민;이원재;소병학;김세경
    • 대한임상독성학회지
    • /
    • 제1권1호
    • /
    • pp.27-33
    • /
    • 2003
  • Purpose: According as the accessibility about drugs becomes various, the occurrence of drug intoxication is increasing. Since report that doxylamine causes rhabdomyolysis often, drug-induced rhabdomyolysis is one of the most important complications in patients with drug intoxication. Acute renal failure (ARF)'s availability is important to the management in rhabdomyolysis, but report about rhabdomyolysis or ARF occurrence for whole intoxicated drugs is lacking up to now. Methods: This research did to 61 patient who had rhabdomyolysis of drug intoxication. First, object patients were divided into two gruops: doxylamine-ingested (Group I) vs non-doxylamine ingested (Group II). And then we analyzed on the early patient's clinical events and laboratory data. We used ROC curve to recognize'the early clinical factors that could forecast ARF appearance among these patients in addition. Results: Almost rhabdomyolysis was happened by doxylamine in drug intoxication ($55.7\%$). However, as compared to group II, group I showed better clinical course, lesser ARF occurrence and hemodialysis requirement. In group II, time was longer in hospital reaching from intoxication, the ARF occurrence rate was higher ($52.6\%$). Analyzing the ROC curve to useful initial factors, they were creatinine, uric acid and interval time from ingestion to hospital. These cut-off values were 1.44 mg/dL, 6.8 mg/dL and 5 hrs. Sensitivity for ARF estimate was $100\%$, specificity $69-98\%$. Conclusion: Compared to group II, Doxylamine-ingested group showed good clinical course. Creatinine, uric acid, interval time from ingestion to hospital aided in ARF estimate in drug-induced rhabdomyolysis.

  • PDF

가스크로마토그래피/질량분석기를 이용한 약물의 확인 및 간이 정량분석 프로그램 개발 (Development of Rapid and Simple Drug Identification and Semi Quantitative Analytical Program by Gas Chromatography-Mass Spectrometry)

  • 김은미;한은영;홍효정;정수진;최상길;이종숙;정진미;염혜선;이한선;이상기
    • 약학회지
    • /
    • 제55권2호
    • /
    • pp.106-115
    • /
    • 2011
  • Systematic toxicological analysis (STA) means the process for general unknown screening of drugs and toxic compounds in biological fluids. In order to establish STA, in previous study we investigated pattern of drugs & poisons in autopsy cases during 2007~2009 in Korea, and finally selected 62 drugs as target drugs for STA. In this study, rapid and simple drug identification and quantitative analytical program by gas chromatography-mass spectrometry(GC-MS) was developed. The in-house program, "DrugMan", consisted of modified chemstation data analysis menu and newly developed macro modules. Total 55 drugs among 62 target drugs were applied to this program, they were 14 antidepressants, 8 anti-histamines, 5 sedatives/hypnotics, 5 narcotic analgesics, 3 antipsychotic drugs, and etc. For calibration curves, fifty five drugs were divided into four groups of range considering their therapeutic or toxic concentrations in blood specimen, i.e. 0.05~1 mg/l, 0.1~1 mg/l, 0.1~5 mg/l or 0.5~10 mg/l. Standards spiked bloods were extracted by solid-phase extraction (SPE) with trimipramine-D3 as internal standard. Parameters such as retention times, 3 mass fragment ions, and calibration curves for each drug were registered to DrugMan. A series of identification, semi quantitation of target drugs and reporting the results were performed automatically. Calibration curves for most drugs were linear with correlation coefficients exceeding 0.98. Sensitivity rate of DrugMan was 0.90 (90%) for 55 drugs at the level of 0.5 mg/l. For standard spiked bloods at the level of 0.5 mg/l for 29 drugs, semi quantitative concentrations were ranged 0.36~0.64 mg/l by DrugMan. If more drugs are registered to database in DrugMan in further study, it will be useful tools for STA in forensic toxicology.

A Nudix Hydrolase Protein, Ysa1, Regulates Oxidative Stress Response and Antifungal Drug Susceptibility in Cryptococcus neoformans

  • Lee, Kyung-Tae;Kwon, Hyojeong;Lee, Dohyun;Bahn, Yong-Sun
    • Mycobiology
    • /
    • 제42권1호
    • /
    • pp.52-58
    • /
    • 2014
  • A nucleoside diphosphate-linked moiety X (Nudix) hydrolase-like gene, YSA1, has been identified as one of the gromwell plant extract-responsive genes in Cryptococcus neoformans. Ysa1 is known to control intracellular concentrations of ADP-ribose or O-acetyl-ADP-ribose, and has diverse biological functions, including the response to oxidative stress in the ascomycete yeast, Saccharomyces cerevisiae. In this study, we characterized the role of YSA1 in the stress response and adaptation of the basidiomycete yeast, C. neoformans. We constructed three independent deletion mutants for YSA1, and analyzed their mutant phenotypes. We found that ysa1 mutants did not show increased sensitivity to reactive oxygen species-producing oxidative damage agents, such as hydrogen peroxide and menadione, but exhibited increased sensitivity to diamide, which is a thiol-specific oxidant. Ysa1 was dispensable for the response to most environmental stresses, such as genotoxic, osmotic, and endoplasmic reticulum stress. In conclusion, modulation of YSA1 may regulate the cellular response and adaptation of C. neoformans to certain oxidative stresses and contribute to the evolution of antifungal drug resistance.

Diagnosis and treatment of multidrug-resistant tuberculosis

  • Jang, Jong Geol;Chung, Jin Hong
    • Journal of Yeungnam Medical Science
    • /
    • 제37권4호
    • /
    • pp.277-285
    • /
    • 2020
  • Tuberculosis (TB) is still a major health problem worldwide. Especially, multidrug-resistant TB (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin, is a barrier in the treatment of TB. Globally, approximately 3.4% of new TB patients and 20% of the patients with a history of previous treatment for TB were diagnosed with MDR-TB. The treatment of MDR-TB requires medications for a long duration (up to 20-24 months) with less effective and toxic second-line drugs and has unfavorable outcomes. However, treatment outcomes are expected to improve due to the introduction of a new agent (bedaquiline), repurposed drugs (linezolid, clofazimine, and cycloserine), and technological advancement in rapid drug sensitivity testing. The World Health Organization (WHO) released a rapid communication in 2018, followed by consolidated guidelines for the treatment of MDR-TB in 2019 based on clinical trials and an individual patient data meta-analysis. In these guidelines, the WHO suggested reclassification of second-line anti-TB drugs and recommended oral treatment regimens that included the new and repurposed agents. The aims of this article are to review the treatment strategies of MDR-TB based on the 2019 WHO guidelines regarding the management of MDR-TB and the diagnostic techniques for detecting resistance, including phenotypic and molecular drug sensitivity tests.

AP-PCR을 이용한 다제내성 Staphylococcus aureus의 유전형 분석 (Genotypic Analysis of Multi-drug Resistant Staphylococcus aureus by Arbitrarily Primed Polymerase Chain Reaction)

  • 신경현;홍승복;손승렬
    • 대한임상검사과학회지
    • /
    • 제36권2호
    • /
    • pp.89-97
    • /
    • 2004
  • Many strains of Staphylococcus aureus were isolated from pus samples from primary, secondary, and tertiary medical institutions and were subjected to an antibiotic sensitivity test. Ciprofloxacin, clindamycin, erythromycin, gentamicin, oxacillin penicillin, tetracycline, trimethoprim/sulfamethoxazole, vancomycin and teicoplanin were used for the antibiotic sensitivity test. The strains showed hightest resistance to penicillin(91%), but all of strains tested were susceptible to vancomycin and teicoplanin. The isolated multi-drug(penicillin-tetracycline-ciprofloxacin-clindamycin-erythromycin- oxacillin-gentamicin) resistant S. aureus were analyzed genotypically using an AP-PCR(Arbitrarily Primed polymerase chain reaction) with an arbitrary 3 primers. Based on the result for genotype analysis, the genotypes identified by S1 primer did not coincide with those of S2 or E2 primers. Genotypes identified by S2 primer did not coincide with those of S1 or E2 primers. Also genotypes identified by the E2 primer did not coincide with those of S1 or S2 primers. Therefore, an analysis of AP-PCR test with multiple primers will provide more sensitive identification. A strain from a secondary medical institution and a strain from a tertiary medical institution which showed the same genotype for S1, S2, and E2 primers are required for further epidemiological study.

  • PDF

LC-ESI-tandem MS를 이용한 기능성표방식품 중 부정유해물질 신속검사체계 개발 (Development of Rapid Analytical Method of Forbidden Medicines in Dietary Supplements Using LC-ESI-Tandem MS)

  • 김희연;장영미;주현진;정용현;이명숙;박종석;이광호;이화미
    • 한국식품과학회지
    • /
    • 제39권4호
    • /
    • pp.372-379
    • /
    • 2007
  • 부정유해물질 총 13종에 대한 신속하고 고감도의 LC-ESI-MS-MS 동시분석 방법을 개발하였으며 바데나필을 포함한 11종은 ESI positive 모드에서 타다라필을 포함한 2종은 ESI negative 모드에서 검출하는 방법으로서 시료 전처리는 간단히 메탄올 추출법을 사용하였다. 기능성표방식품 중 부정유해물질의 확인은 한번 시료를 주입함으로써 15분 이내에 13종의 분석이 가능하고 크로마토그램의 분리는 아세토니트릴과 10mM ammonium formate가 들어있는 탈이온수를 이용한(pH 7.0) 기울기 용매 조건으로 수행하였다. 확립한 13종에 대한 부정유해물질 분석방법은 검출 한계(LOD)는 0.1-5 ng/mL이고, 정량한계(LOQ)는 0.1-10 ng/mL으로서 평균 상관계수$(r^2)$는 0.9853로서 ppb 수준에서 정량성을 가지며 회수율은 87.5-98.5%, 변동계수는 15% 이하임을 확인할 수 있었다. 또한 확립한 시험방법 LC/MS/MS를 이용하여 147건의 기능성표방식품 중의 부정유해물질의 검증을 실시한 결과, 유해물질의 검출이 나타타지 않음을 알 수 있었다. 기능성표방식품 중의 실데나필과 그 유사물질을 포함한 13종의 부정유해물질에 대한 스크리닝 방법으로 MRM 모드를 이용한 LC-ESI-MS-MS 방법을 개발하였으며, 이는 유해물질에 대한 고성능액체크로마토그래피/자외선흡광광도법의 선택성등의 제한성을 극복한 부정유해 물질의 스크리닝에 신속하고 미량까지 검출 가능한 가치 있는 방법임을 확인할 수 있었다.

miR-126 Suppresses the Proliferation of Cervical Cancer Cells and Alters Cell Sensitivity to the Chemotherapeutic Drug Bleomycin

  • Yu, Qing;Liu, Shan-Ling;Wang, He;Shi, Gang;Yang, Pei;Chen, Xin-Lian
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권11호
    • /
    • pp.6569-6572
    • /
    • 2013
  • In cervical cancer, one of the most common malignant tumors in women worldwide, miR-126 has been reported to exhibit decreased expression. However, its role in cervical cancer cell proliferation and drug sensitivity has remained relatively unexplored. Here, we compared the expression of miR-126 in cervical cancer tissues (n = 20) with that in normal cervical tissue (n = 20) using quantitative RT-PCR. The viability of Siha cervical cancer cells was further measured by MTT assay after transfection with miR-126 mimic (Siha-miR-126 mimic) or microRNA mimic negative control (Siha-miR mimic NC) and after treatment with various concentrations of bleomycin (BLM). IC50s were calculated, and the survival rates (SRs) of Siha cells were calculated. miR-126 expression in cervical cancer tissue was significantly decreased compared with that in normal cervical tissue (P < 0.01). The relative SRs of Siha-miR-126 mimic cells were also significantly decreased compared with those of Siha-miR mimic NC cells at 24-96 h after transfection. The IC50 of BLM in Siha-miR-126 mimic cells ($50.3{\pm}2.02{\mu}g/mL$) was decreased compared with that in Siha-miR mimic NC cells ($70.5{\pm}4.33{\mu}g/mL$) at 48 h after transfection (P < 0.05). Finally, the SRs of Siha-miR-126 mimic cells were significantly lower than those of SihamiR mimic NC cells after cultured in medium containing 40 ${\mu}g/mL$ BLM for 24-96 h (P < 0.05). These results suggest that miR-126 is expressed at low levels in cervical cancer. Upregulation of miR-126 inhibited cervical cancer cell proliferation and enhanced the sensitivity to BLM. Thus, miR-126 may represent a novel approach to cervical cancer treatment.

Cyclophosphamide가 마우스의 면역기억에 미치는 영향 (Effects of Cyclophosphamide on Immunological Memory in Mice)

  • 박영민;박윤규;안우섭;하대유
    • 대한미생물학회지
    • /
    • 제22권2호
    • /
    • pp.175-184
    • /
    • 1987
  • The use of alkylating agent cyclophosphamide(CY), a widely used antitumor drug is well known as a potent immunosuppressant and has been used as a probe for investigating the functional capabilities of lymphocyte subsets of both T and B cells that play an important role in the regulation of the immune response. The present study was undertaken in an effort to assess the effects of CY on immunological memory in murine model. CY, given as a single dose of CY(250mg/kg) before sensitization with sheep red blood cells(SRBC) enhanced the primary response of Arthus and delayed-type hypersensitivity(DTH), as measured by footpad swelling reaction, but suppressed their tertiary DTH response. The similar CY pretreatment enhanced both the primary and tertiary hemagglutinin(HA) responses to SRBC, and the tertiary antibody response against polyvinylpyrroridone(PVP), a thymus-independent antigen but not the primary response against PVP. CY, given as a single dose of 250mg/kg 2 days before the primary immunization and two doses of 100mg/kg 2 days before the secondary and tertiary immunization, markedly suppressed the tertiary DTH and HA responses to SRBC. However, CY, given as small multiple daily doses(10mg/kg) over 4 days before sensitization but not after sensitization, enhanced the secondary HA response to SRBC. Contact sensitivity to dinitrofluorobenzene(DNFB) was suppressed by the drug, given either as a single large dose(300mg/kg) or as multiple dose(10mg/kg) administered 2 days before, together with or after DNFB sensitization. This suppression was more pronounced and more significant when CY was given as multiple dose. However, the enhancement of the secondary contact sensitivity to DNFB by CY was not clear-cut. The splenectomy appears to increase the enhancing effect of CY on contact sensitivity. These results suggest that CY selectively influences the immune response depending on the time of the drug administration relative to immunization and that the secondary or tertiary immune response involve memory cells with different susceptibilities to CY. Moreover, these results suggest that multiple low doses may sesectivley inhibit suppressor T cell proliferation involving DTH, HA or contact sensitivity without effecting helper T cells, but high doses presumably inhibit helper T cells and suppressor T cells with effecting B cells.

  • PDF

고위험병원체 결핵균의 신속진단을 위한 액체배양시스템 평가 (Evaluation of Liquid Culture System in Sputum Culture and Drug Susceptibility of Mycobacterium tuberculosis)

  • 김진숙;김승철;전보영;박승규
    • 미생물학회지
    • /
    • 제45권3호
    • /
    • pp.281-285
    • /
    • 2009
  • 본 연구에서는 객담 내 결핵균의 배양시험과 약제 감수성 시험 방법으로서 BacT/Alert 액체 배지, Ogawa 배지 및 $L\ddot{o}wenstein$-Jensen 배지 배양법을 비교하였다. 신속 액체배양시스템은 기존의 Egg-based media (Ogawa, $L\ddot{o}wenstein$-Jensen 배지)에 비해 높은 민감도와 빠른 배양으로 결핵환자의 초기 객담 검사와 약제 감수성 시험에 널리 사용되어 왔다. 객담은 N-Acetyl-L-cystine과 4% NaOH로 처리한 후 BacT/Alert 액체 배지 시스템과 Ogawa 배지에 접종하고 배양하여 비교하였다. 결핵환자 객담 검체 135개 중 도말검사결과 양성은 95개였고, Ogawa 배지 배양결과 양성으로 확인된 수는 89개(65.9%)였으며, BacT/Alert 액체 배지에서는 97개(71.9%)가 양성으로 확인되었다. 결핵균 배양 양성 검체의 평균배양일은 Ogawa 배지에서 22.4일, BacT/Alert 액체 배지는 11.3일로 단축되는 것을 확인하였다. 약제 감수성 시험에는 32개 결핵균주를 이용하였으며, isoniazid를 첨가한 BacT/Alert 액체 배지와 $L\ddot{o}wenstein$-Jensen 배지에서의 약제 감수성 시험 검사결과 일치률은 87.5%를 보였고, rifampicin에서의 일치률은 90.6%로 나타났다.

수산물 중 에톡시퀸의 LC-MS/MS 정량분석법 개발 (Development of LC-MS/MS Quantitation Method for Ethoxyquin in Fishery Products)

  • 신다솜;채영식;강희승;이수빈;조윤제;천소영;정지윤;이규식
    • 한국식품위생안전성학회지
    • /
    • 제31권6호
    • /
    • pp.432-438
    • /
    • 2016
  • 본 연구는 수산물 중 에톡시퀸 정량시험법을 확립하여 국내 생산 및 수입 양식 수산물에 대한 잔류할 수 있는 동물용의약품인 에톡시퀸에 대한 안전관리 강화기반을 위해 마련되었다. LC-MS/MS를 이용하여 신속하고 효과적으로 정량성 및 정밀성을 확보하였으며, 확립된 시험법의 선택성, 정량한계 및 회수율에 대한 검증을 통하여 에톡시퀸 시험법으로서의 유효성을 확인하였다. 표준용액을 정량한계를 포함한 농도에 따라 검량선을 작성한 결과 $r^2$> 0.99 이상의 직선성을 확인하였으며, 산성용매로 추출 후 MCX 카트리지를 이용해 정제하였다. 본 실험에서의 검출한계는 0.001 mg/kg, 정량한계는 0.01 mg/kg 수준이었고, 평균 회수율은 81.3~107%이었다. 또한, 분석오차는 10% 이하로 정확성 및 재현성이 우수하였으며, CODEX 가이드라인 규정에 만족하는 수준이었다. 따라서, 개발된 시험법은 안전한 국내유통 수산물과 국민보건을 위해 지속적인 잔류실태조사에 활용되고, 수산물 중 잔류동물용의약품의 안전관리에 기여할 것으로 판단된다.